- WPD Pharmaceuticals (CSE:WBIO) has engaged ImQuest Biosciences to expand in-vitro and in-vivo testing of its WP1122 drug
- The company’s license partner, Moleculin Biotech, entered into the agreement with ImQuest
- WP1122 is the company’s leading potential COVID-19 drug candidate
- The company recently announced that an active ingredient in WP1122 reduced replication of the SARS-CoV-2 virus by 100 per cent
- WPD Pharmaceuticals (WBIO) is down 1.27 per cent, and is currently trading for C$0.78 per share
WPD Pharmaceuticals (CSE:WBIO) has engaged ImQuest Biosciences to expand in-vitro and in-vivo testing of its WP1122 drug.
The company’s license partner, Moleculin Biotech, entered into the agreement, to further explore WP1112’s potential as a COVID-19 treatment. WP1122 is currently WPD’s leading drug candidate for treating the coronavirus pandemic.
On April 9, the company announced a breakthrough discovery one of the drug’s active ingredients. Independent research found that a WP1122 component, 2-deoxy-D-glucose, had a significant impact on COVID-19. Specifically, the molecule reduced the virus replicating by 100 per cent, in in-vitro testing.
While this sounds promising, WPD cannot currently claim the ability to eliminate, cure, or contain COVID-19. However, with the help of ImQuest Biosciences, WPD plans to explore the drug’s potential.
ImQuest is a leading preclinical contract research and development organisation (CRO). It provides services, allowing companies to evaluate if new pharmaceutical products could treat or prevent diseases. Specifically, ImQuest evaluates products which may work against infectious diseases, cancers, and inflammatory conditions.
Right now, the world is struggling against the most serious pandemic in recent memory. As a result, pharmaceutical companies worldwide are working urgently to develop deterrents, treatments, and vaccines for COVID-19.
ImQuest has already developed a robust platform, through which it can identify and develop therapeutic products which may treat coronavirus.
The services that ImQuest will provide to WPD are a part of its ImQuestSUCCESS Platform. Those services will include compound screening, drug target evaluation, and product potential evaluation.
WPD Pharmaceuticals (WBIO) is down 1.27 per cent, and trading for $0.78 per share, as of 11:26am EST.
